These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Platelet GPIIb/IIIa receptor inhibition by SC-49992 prevents thrombosis and rethrombosis in the canine carotid artery. Rote WE; Werns SW; Davis JH; Feigen LP; Kilgore KS; Lucchesi BR Cardiovasc Res; 1993 Mar; 27(3):500-7. PubMed ID: 8490951 [TBL] [Abstract][Full Text] [Related]
5. Thrombolytic effects of recombinant fibrolase or APSAC in a canine model of carotid artery thrombosis. Markland FS; Friedrichs GS; Pewitt SR; Lucchesi BR Circulation; 1994 Nov; 90(5):2448-56. PubMed ID: 7955202 [TBL] [Abstract][Full Text] [Related]
6. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis. Przyklenk K; Kloner RA Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780 [TBL] [Abstract][Full Text] [Related]
7. Antithrombotic effects of DMP 728, a platelet GPIIb/IIIa receptor antagonist, in a canine model of arterial thrombosis. Rote WE; Davis JH; Mousa SA; Reilly TM; Lucchesi BR J Cardiovasc Pharmacol; 1994 Apr; 23(4):681-9. PubMed ID: 7516023 [TBL] [Abstract][Full Text] [Related]
8. TP-9201, a glycoprotein IIb/IIIa platelet receptor antagonist, prevents rethrombosis after successful arterial thrombolysis in the dog. Rebello SS; Driscoll EM; Lucchesi BR Stroke; 1997 Sep; 28(9):1789-96. PubMed ID: 9303027 [TBL] [Abstract][Full Text] [Related]
9. Prevention of thrombosis and rethrombosis and enhancement of the thrombolytic actions of recombinant tissue-type plasminogen activator in the canine heart by DMP728, a glycoprotein IIb/IIIa antagonist. Lucchessi BR; Rote WE; Driscoll EM; Mu DX Br J Pharmacol; 1994 Dec; 113(4):1333-43. PubMed ID: 7889289 [TBL] [Abstract][Full Text] [Related]
11. Antithrombotic effect of GYKI-14766 in a canine model of arterial and venous rethrombosis: a comparison with heparin. Sudo Y; Lucchesi BR J Cardiovasc Pharmacol; 1996 Apr; 27(4):545-55. PubMed ID: 8847872 [TBL] [Abstract][Full Text] [Related]
12. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis. Nicolini FA; Nichols WW; Saldeen TG; Mehta JL Cardiovasc Res; 1991 Apr; 25(4):283-9. PubMed ID: 1909212 [TBL] [Abstract][Full Text] [Related]
13. Effects of adenosine on thrombosis and thrombolysis in a canine experimental preparation. Huang J; Feldbaum VM; Lucchesi BR; Werns SW Pharmacology; 2001; 63(3):166-74. PubMed ID: 11598423 [TBL] [Abstract][Full Text] [Related]
14. Thrombolytic and antithrombotic efficacy of the platelet GPIIb-IIIa antagonist DMP728. Mousa SA; Forsythe MS; Diemer M; Bozarth JM; Reilly TM Coron Artery Dis; 1994 Nov; 5(11):919-27. PubMed ID: 7719524 [TBL] [Abstract][Full Text] [Related]
15. Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model. Huang J; Driscoll EM; Gonzales ML; Park AM; Lucchesi BR J Pharmacol Exp Ther; 2000 Nov; 295(2):492-9. PubMed ID: 11046080 [TBL] [Abstract][Full Text] [Related]
16. Endogenous and exogenous nitric oxide protect against intracoronary thrombosis and reocclusion after thrombolysis. Yao SK; Akhtar S; Scott-Burden T; Ober JC; Golino P; Buja LM; Casscells W; Willerson JT Circulation; 1995 Aug; 92(4):1005-10. PubMed ID: 7641335 [TBL] [Abstract][Full Text] [Related]
17. Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein IIb/IIIa receptors. Haskel EJ; Adams SP; Feigen LP; Saffitz JE; Gorczynski RJ; Sobel BE; Abendschein DR Circulation; 1989 Dec; 80(6):1775-82. PubMed ID: 2513145 [TBL] [Abstract][Full Text] [Related]
18. Correlation between the in vivo efficacy of GPIIb/IIIa receptor antagonists (m7E3, MK-383 and DMP-728) and ex vivo platelet inhibition. Huang J; Rebello SS; Faul JD; Lucchesi BR Pharmacology; 1999 May; 58(5):252-64. PubMed ID: 10087466 [TBL] [Abstract][Full Text] [Related]
20. Prevention of reocclusion following tissue type plasminogen activator-induced thrombolysis by the RGD-containing peptide, echistatin, in a canine model of coronary thrombosis. Holahan MA; Mellott MJ; Garsky VM; Shebuski RJ Pharmacology; 1991; 42(6):340-8. PubMed ID: 1946598 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]